Major Institutional Buy-In for Vericel
In a significant move within the biotechnology sector, Soleus Capital Management has reported a substantial increase in its position in Vericel (NASDAQ:VCEL). According to an SEC filing dated May 14, 2026, the investment firm added 1,785,079 shares during the first quarter. Based on the quarterly average pricing, this investment is estimated to be valued at approximately $63.40 million. Following this acquisition, Vericel now accounts for 3.32% of Soleus Capital’s total 13F assets under management.
Understanding the Business Model
Vericel is a commercial-stage biopharmaceutical company that focuses on the development and marketing of autologous cell therapy products. The company primarily serves the sports medicine and burn care markets, providing specialized treatments to hospitals, clinics, and medical centers across the United States. Its core product portfolio includes:
- MACI: A therapy utilized for cartilage repair.
- Epicel: A treatment designed for severe burns.
- NexoBrid: A product currently in the preapproval stage for burn care.
Financial Performance and Growth Drivers
Despite a challenging year for the stock, which has seen a decline of approximately 20% compared to a 28% gain in the S&P 500, the underlying business operations remain robust. Vericel recently reported a 20% year-over-year revenue increase to $63.2 million for the second quarter. Key financial highlights include:
- Segment Growth: Flagship product MACI saw a 21% increase in revenue.
- Margin Expansion: Gross margins reached 74%, reflecting a four-percentage-point improvement over the previous year.
- Profitability: Adjusted EBITDA more than doubled to $13.4 million.
- Strong Balance Sheet: The company concluded the quarter with roughly $164 million in cash and investments, maintaining a debt-free status.
Future Outlook
Vericel management, led by CEO Nick Colangelo, maintains a positive outlook for the remainder of the year, citing continued momentum from the MACI Arthro launch. Furthermore, the company has received FDA clearance to initiate a Phase 3 study evaluating MACI for ankle cartilage defects, which represents a new potential avenue for expansion. For investors, the combination of growing revenue, improving margins, and a healthy cash position appears to be a significant factor in the continued interest from specialized healthcare funds, even amidst recent stock price volatility.
